cholecalciferol and lanthanum-carbonate

It is widely known that dialysis patients who are administered vitamin D preparations have a better prognosis than patients who are not. In this study, of 22 patients on maintenance dialysis who had been administered calcium (Ca) carbonate in our hospital, we investigated the dosage amount of vitamin D3 preparations after the phosphorus (P) binder was switched from Ca carbonate to the newly developed lanthanum carbonate (LC). After completely switching to LC, the dosage amount of oral vitamin D3 preparation (alfacalcidol equivalent) was significantly increased from 0.094 μg/day to 0.375 μg/day (P = 0.0090). No significant changes were observed in the values of serum corrected Ca, alkaline phosphatase, intact parathyroid hormone and P after switching. The administration of LC enabled complete cessation of the administration of Ca carbonate preparations, and increased the dosage amount of vitamin D3 preparations. Therefore, LC may be a useful P binder to improve patient prognosis.

Topics: Administration, Oral; Aged; Alkaline Phosphatase; Calcium; Calcium Carbonate; Cholecalciferol; Dose-Response Relationship, Drug; Female; Humans; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Prognosis; Renal Dialysis; Retrospective Studies